Here at CLL Society, we are actively monitoring changes in the federal government agencies that may affect federal employees’ ability to continue to serve our patients in progressing innovation and ensuring oversight of insurance coverage and accessibility to treatments.
Just the facts, and without political commentary, CLL Society will continue to focus on government actions and policies that affect our patients.
So far, voluntary resignation numbers at the Food and Drug Administration (FDA) and Centers for Medicare and Medicaid Services (CMS) are not available, but across all agencies, there has been less than a 3% attrition. To put this in perspective, this is less than half of typical annual attrition in any given year.
Last year the FDA employed almost 19,700 people. Of those, 7,580 work in CDER (Center for Drug Evaluation and Research) and 1,643 in CBER (Center for Biologics Evaluation and Research). We are tracking changes that may come in the form of funds that will be appropriated by Congress for the agency as well as through Reductions in Force (RIFs) and changes in federal employee policies (e.g., offers of deferred resignation, reclassification of employees, return-to-work policies, etc.).
Uniquely at the FDA, the fiscal year 2025 budget request highlights that nearly 70% of CDER staff and 50% of CBER staff are funded through user fees, meaning that reducing these positions would not result in savings for taxpayers or the government.
